Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2017

View Archived Issues

New phase II trial investigates savolitinib for pulmonary sarcomatoid carcinoma in China

Takeda announces plans to spin off its Japan Consumer Healthcare Business Unit

Merck KGaA compares MSB-11022 to Humira in phase III trial for rheumatoid arthritis

Varlitinib receives orphan drug designation in Korea for biliary tract cancer

Novel HIV capsid inhibitors created at Gilead

Discuva and Roche extend collaboration to tackle antibiotic-resistant infections

SLCO2B1 polymorphism predicts poor response to abiraterone acetate in mCRPC patients

Neovacs and BioSense sign Chinese commercial license option agreement for IFN-alpha kinoid

Immuron announces completion of IMM-124E phase II NASH clinical trial recruitment

Encouraging results seen with pretomanid in NIX-TB Trial

Global HOPE pediatric hematology-oncology initiative launched in Africa

LAB282 drug discovery partnership awards first grants

Neurocognitive effects of cenicriviroc assessed in phase II study

European Commission grants conditional marketing authorization for Alecensa

Enigma Biomedical and McGill University sign research agreement for tau imaging agent MK-6240

FDA awards fast track designation to CMD-003

Phase II results for savolitinib show promise in MET-driven papillary renal cell carcinoma patients

Samumed identifies novel Wnt signaling and IL-6 production inhibitors

NantWorks/Nant Holdings patent thiosemicarbazone derivatives

Millennium Pharmaceuticals receives U.S. orphan designation for cancer candidate TAK-659

Nelfinavir named orphan drug in the U.S. for multiple myeloma

Novel TNF-alpha antagonists synthesized at Bristol-Myers Squibb

U.S. orphan drug status granted to decitabine plus tetrahydrouridine for thalassemia

Amgen discovers beta-secretase inhibitors

Vitae Pharmaceuticals discloses novel nuclear receptor ROR-gamma modulators

Raze Therapeutics presents novel MTHFD2 inhibitors